Drug intelligence / Profile preview

bifidobacterium (Xijing Hospital)

Development stage: Preclinical
Lead developer: Xijing Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium is a genus of probiotic bacteria being investigated as a live biotherapeutic product for its potential metabolic benefits. Xijing Hospital is conducting clinical trials to assess the effects of Bifidobacterium, in combination with berberine hydrochloride, on lowering blood glucose and preventing the progression to diabetes in individuals with prediabetes and type 2 diabetes. [17] The proposed mechanisms of action include modulating the gut microbiota, improving gut barrier function, reducing inflammation and endotoxemia, increasing beneficial metabolites like short-chain fatty acids (SCFAs), and potentially modulating incretin hormones such as GLP-1 to improve insulin sensitivity and glucose metabolism. [18, 21, 24, 26]

Other names: bifidobacterium-Xijing Hospital-prediabetes

Beyond the preview

Go deeper on bifidobacterium (Xijing Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium (Xijing Hospital).

Explore the full profile